239 episodes

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

The Readout Loud STAT

    • Business
    • 4.6 • 260 Ratings

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

    237: The 'electric vehicles' of pharma, Illumina's boondoggle, & a Theranos sentencing

    237: The 'electric vehicles' of pharma, Illumina's boondoggle, & a Theranos sentencing

    STAT's Elaine Chen joins us to explain how the escalating demand for a potent diabetes drug is putting patients with obesity in a difficult situation. We also discuss a curious trend in biotech investing, the future of Illumina, and another sentencing in the Theranos saga.

    • 35 min
    236: Wither PhRMA, Alzheimer's treatment data revealed, and the first fecal microbiome drug approval

    236: Wither PhRMA, Alzheimer's treatment data revealed, and the first fecal microbiome drug approval

    STAT Washington correspondent Rachel Cohrs joins us to explain how PhRMA, the all-powerful lobbying group, lost its edge in a fight over drug-pricing negotiation. Damian gives us the inside scoop on CTAD, the big Alzheimer's disease research conference, where Eisai and Biogen presented groundbreaking data on their treatment called lecanemab. We also discuss the FDA approval of a microbiome drug for the treatment of a bowel disorder and the potential for a big acquisition of Horizon Therapeutics.

    • 33 min
    235: LIVE from the STAT Summit

    235: LIVE from the STAT Summit

    How do Alzheimer’s drugs even work? Can biotech people bake? And do we even like one another? Recorded live from the 2022 STAT Summit, we discuss the failure of an Alzheimer’s disease treatment from Roche, the unexpected success of a competing one for Eisai, and some unpredictable questions from our audience.

    • 28 min
    234: Biogen's new CEO, how the midterms affect science, & a biotech bankruptcy

    234: Biogen's new CEO, how the midterms affect science, & a biotech bankruptcy

    STAT Washington correspondent Sarah Owermohle joins us to explain how this week's midterm elections will affect health and medicine, and what the politicization of the pandemic means for the future of science in the U.S. We also discuss the incoming CEOs of Biogen and Seagen, plus a pair of biotech collapses.

    • 32 min
    233: How the biotech revolution could come apart at the seams

    233: How the biotech revolution could come apart at the seams

    Our colleague Matthew Herper joins us to discuss his thoughtful, personal story on how the biotech revolution that brought us genome editing, Covid-19 vaccines, and lifesaving medicines could run aground if humanity can't get out of its own way.

    • 29 min
    232: Anti-science at the polls, a biotech odd couple, & the stakes of the midterms

    232: Anti-science at the polls, a biotech odd couple, & the stakes of the midterms

    Our colleague Sarah Owermohle joins us to discuss how pandemic shutdowns, Covid-19 vaccines, and the prospect of arresting Anthony Fauci have become campaign rallying cries in midterm elections. We also discuss the latest news in the life sciences, including the potential effects of federal drug-price negotiation and the virtues of befriending Pharrell Williams.

    • 23 min

Customer Reviews

4.6 out of 5
260 Ratings

260 Ratings

ocean 1435🐾 ,

Love this

Hi i love the podcast❤️❤️❤️❤️❤️❤️

reportinghygeine ,

Wrong Tone On the Murder for Hire

It sounds like someone was killed. If it was one of your close relatives you would be furious about the tone. Murder is serious, not funny, although I do understand that it’s not usually your beat. You come off as young, naive and lacking in character and wisdom.

CxxxxLxxxxx ,

Great for people who follow the biotech industry

Does a great job of reporting on and discussing the important developments in the biotech industry.

Top Podcasts In Business

iHeartPodcasts
NPR
Ramsey Network
Morning Brew
Jocko DEFCOR Network
Andy Frisella #100to0

You Might Also Like

BioCentury
Timmerman Report
Tradeoffs
Kaiser Health News
Andreessen Horowitz
Andreessen Horowitz